Compare ConocoPhillips (COP) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Cassava Sciences Inc — how do they compare? ConocoPhillips trades at $133.54 (market cap $155.98B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: ConocoPhillips is far larger — about 3958.9× Cassava Sciences Inc's market cap, and ConocoPhillips pays a 2.59% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Cassava Sciences Inc for 37 Days on average.
| COP | FLNA | |
|---|---|---|
Market Cap | $155.98B | $39.40M |
Volume | 4,774,951 | 759,018 |
Sector | Energy | Health |
52-Week High | $141.22 | $4.64 |
52-Week Low | $85.66 | $0.68 |
Typical Hold Time | 79 Days | 37 Days |
Enterprise Value | $171.58B | -$43.28M |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.19, up 3.74% with strong technical momentum and bullish moving averages. The company shows solid fundamentals with Q2 2026 EPS beating expectations at $3.24 versus $2.90, supported by a 20-year LNG supply agreement with Venture Global announced October 1, 2026. Valuation metrics remain reasonable with P/E of 17.17 and EV/EBITDA of 6.17, while analyst consensus favors Buy ratings (75%) with a $154.75 price target.
Outlook remains positive given robust cash flow generation and strategic LNG expansion, though risks include oil price volatility and geopolitical exposure. The stock offers value with upside potential to analyst targets, but investors should monitor execution on international asset sales and energy market dynamics.
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
